Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 20/20 | 0.70 |
| ▸ | CDK2 | P24941 | 20/20 | 0.70 |
| ▸ | KDR | P35968 | 17/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13022041 | 1.00 | CDK1 (0.70) | CDK1CDK2KDR | |
| SCHEMBL12390726 | 0.89 | CDK2 (0.57) | CDK1CDK2KDR | |
| SCHEMBL1416531 | 0.89 | CDK2 (0.57) | CDK1CDK2KDR | |
| SCHEMBL13944388 | 0.83 | CDK2 (0.78) | CDK1CDK2KDR | |
| SCHEMBL3934409 | 0.83 | CDK1 (1.00) | CDK1CDK2KDR | |
| SCHEMBL3929323 | 0.83 | CDK1 (1.00) | CDK1CDK2KDR | |
| SCHEMBL13022036 | 0.82 | CDK2 (0.54) | CDK1CDK2KDR | |
| SCHEMBL2820448 | 0.82 | CDK2 (0.54) | CDK1CDK2KDR | |
| SCHEMBL3937430 | 0.81 | CDK1 (1.00) | CDK1CDK2KDR | |
| SCHEMBL13890224 | 0.80 | CDK1 (0.47) | CDK1CDK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170839-B1 | ALKYNYLPYRIMIDINES AS TIE2 KINASE INHIBITORS | BAYER IP GMBH (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-8642611-B2 | Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8524724-B2 | — | — | 2013-09-03 | — | — | US | disclosed |
| US-7825128-B2 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| US-20090099219-A1 | ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2022785-A1 | Alkynylpyrimidines as Tie2 kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-11 | — | — | EP | disclosed |
| EP-1963282-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007071455-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099219-A1 | ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, FLT1 | CDK1 372/4885CDK2 64/4885KDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.